Divisadero Street Capital Management LP Has $5.72 Million Stake in Harrow, Inc. $HROW

Divisadero Street Capital Management LP reduced its holdings in Harrow, Inc. (NASDAQ:HROW) by 15.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 118,670 shares of the company’s stock after selling 21,900 shares during the quarter. Divisadero Street Capital Management LP’s holdings in Harrow were worth $5,718,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in Harrow during the 2nd quarter worth approximately $48,000. State of Alaska Department of Revenue acquired a new position in shares of Harrow in the third quarter valued at approximately $83,000. Tower Research Capital LLC TRC increased its position in shares of Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after acquiring an additional 2,615 shares in the last quarter. Strs Ohio bought a new stake in shares of Harrow during the first quarter worth $149,000. Finally, AlphaQuest LLC raised its holdings in shares of Harrow by 743.0% during the third quarter. AlphaQuest LLC now owns 3,819 shares of the company’s stock worth $184,000 after acquiring an additional 3,366 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HROW. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. HC Wainwright boosted their price target on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research report on Tuesday, March 3rd. Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 3rd. Finally, Cantor Fitzgerald reduced their price target on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $71.14.

Harrow Stock Down 4.1%

HROW stock opened at $34.10 on Monday. Harrow, Inc. has a twelve month low of $20.85 and a twelve month high of $54.85. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -200.58 and a beta of 0.05. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The business has a 50 day moving average price of $46.23 and a two-hundred day moving average price of $43.67.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.